| 產(chǎn)品編號(hào) | BIO0978SM |
| 英文名稱(chēng) | Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab Biosimilar) |
| 別 名 | Complement C5 & Serum Albumin / SA / HSA; Gefurulimab |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 28.99kDa |
| 性 狀 | Lyophilized |
| 亞 型 | VHH-VHH |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Gefurulimab with complement protein, then with the addition of Rituximab and Raji cells and incubated for 4 hours. CTG was used to detect the luciferase signal. As shown in fig, Gefurulimab can block rituximab-induced CDC killing, and the IC50 was 18.090 nM.
Gefurulimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Gefurulimab bound to HSA-Fc , and the EC50 was 0.006 nM.
The purity of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 100.00%, determined by SEC-HPLC.
Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 28.99 kDa.
|
